Abbott Laboratories (ABT)
Last Price$126.3(0.3%)
Market Cap$218.8B
ABT Rating
ABT Quality rating performance
ABT Intrinsic Value
Key Highlights:
As of Mar 21, 2025 ABT Relative Value is $159.3, which is undervalued by 26.1%, compared to current share price of $126.3.
As of Mar 21, 2025 ABT DCF Value is $216.7, which is undervalued by 71.5%, compared to current share price of $126.3.
ABT Share Price History
1W (0.3%)
1M (6.4%)
6M 11.1%
YTD 17.9%
1Y 15.6%
3Y 9.9%
5Y 119.6%
10Y 222.0%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
ABT Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$218.8B
$225.8B
$42.0B
$6,351.0M
Shares Outstanding
1,732M
Employees
114K
Growth (CAGR)
5.6%
29.93%
(33.42%)
Profitability
55.6%
16.6%
31.9%
20.4%
15.1%
47.4%
Intrinsic Value
$187.7 (48.6% undervalued)
$216.2
$159.1
($95.8)
($175.4)
89.9%
Return on Capital
Financial Health
$7,967.0M
$7,054.0M
1.1x
17.5x
31.4%
Dividends
13.4%
1.8%
60.4%
Apr 15, 2025
Earnings
Jul 16, 2025
MISS by (0.5%)
MISS by 0.0%
25.2%
8 Beat & 2 Miss
ABT Stock Financials
ABT Income Statement Metrics
Annual
Quarterly
LTM
ABT Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
$8,558.0M +17.9% YoY
Capital Expenditure (CAPEX)
($2,207.0M) +0.2% YoY
Free Cash Flow (FCF)
$6,351.0M +25.5% YoY
ABT Income Statement Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
$42.0B 4.6% YoY
Cost of revenue
$18.7B 4.1% YoY
Pre-tax income
$7,013.0M 5.2% YoY
16.7% margin
ABT Balance Sheet Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$81.4B
Current assets ($23.7B, 29.1% of total)
$7,967.0M (9.8%)
$9,495.0M (11.7%)
Other current assets
$6,194.0M (7.6%)
Non-current assets ($57.8B, 70.9% of total)
$886.0M (1.1%)
$10.7B (13.1%)
$6,647.0M (8.2%)
Other non-current assets
$39.6B (48.6%)
Financial position
$7,054.0M
Cash & Short-term
Investments
Total Debt
ABT Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
ABT Earnings Surprises
Crunching data... Almost there!
ABT Dividends
ABT Dividend Yield
Crunching data... Almost there!
ABT Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with ABT
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$218.8B | 7.1 | $187.7 48.6% undervalued | 15.6% | $42.0B | $6,351.0M | 4.6% | 15.1% | 55.6% | 25.3% | 31.4% | |
$148.2B | 6.8 | $37.4 62.9% overvalued | 49.0% | $16.7B | $2,438.0M | 17.6% | 14.6% | 67.0% | 8.0% | 50.7% | |
$141.4B | 6.7 | $305.8 17.6% overvalued | 5.9% | $22.6B | $3,487.0M | 10.2% | 15.4% | 62.8% | 10.4% | 65.9% | |
$115.8B | 6.4 | $122.4 35.5% undervalued | 11.1% | $33.2B | $5,467.0M | 2.7% | 16.5% | 62.9% | 7.4% | 53.6% | |
$41.6B | 6.1 | $56.4 20.0% overvalued | (25.6%) | $5,724.3M | $289.9M | (4.7%) | 5.1% | 78.4% | 21.6% | 7.0% | |
$29.5B | 7.3 | $40.2 45.6% overvalued | (44.7%) | $4,033.0M | $630.7M | 11.3% | 15.6% | 60.4% | 21.7% | 120.3% | |
$23.6B | 5.3 | $72.8 185.6% undervalued | 29.4% | €18.0B | €1,145.0M | (0.8%) | 6.4% | 43.1% | (4.2%) | 63.4% | |
$22.4B | 5.8 | $185.6 67.6% undervalued | (12.1%) | $7,678.6M | $1,132.4M | 3.8% | 14.7% | 66.0% | 6.3% | 43.0% | |
$21.7B | 6.4 | $204.3 7.3% overvalued | (2.0%) | $5,398.4M | $751.4M | (0.2%) | 13.9% | 44.7% | 8.2% | 35.6% | |
$18.8B | 7.9 | $107.4 60.0% overvalued | 61.0% | $1,900.3M | $303.0M | 12.0% | 15.9% | 76.4% | 26.9% | 6.9% | |
$12.5B | 7.9 | $153.5 54.2% overvalued | 21.2% | $788.0M | $166.1M | 41.4% | 21.1% | 87.0% | 31.2% | 103.3% |
FAQ
What is Abbott Laboratories (ABT) stock rating?
As of today, Abbott Laboratories has a stock rating of 7 (out of 10), which is considered Great.
is Abbott Laboratories (ABT) a good stock to buy?
As of today, Abbott Laboratories has a Great stock rating, which is 48.6% undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 12.8%.